CytomX Therapeutics, Inc.
CTMXStock
$3.67+53.33%52W
Market Cap$795.70M
P/E23.50x
Div yield—
Beta2.16
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-23.88%
Price vs S&P 500 (4W)25.00%
VGM Score29.24
Market Capitalization$795.70M
P/E Ratio (Annual)23.50x
Earnings Surprise History
Q1 26-0.10est. -0.12
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.33
4.33
4.40
4.36
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CTMXCytomX Therapeutics, Inc. | D | F | C | $3.67 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
CytomX Therapeutics is a clinical-stage oncology company developing probody therapeutics—masked, conditionally activated biologics designed to target the tumor microenvironment. The company's proprietary technology platform creates cancer immunotherapies that activate specifically in tumors while remaining inactive in healthy tissues, enhancing efficacy and reducing potential side effects.